News
AMAL Therapeutics to publish research outcomes in Cancers
Geneva, Switzerland, October 20, 2022 – AMAL Therapeutics is pleased to announce that the latest findings of its research team is online on the Cancers website.
Laetitia Devy Dimanche takes over CEO position on September 1st, 2022
Geneva - September 1st, 2022 - Laetitia Devy Dimanche is taking over CEO position from Madiha Derouazi
Madiha Derouazi and Elodie Belnoue honoured at the European Inventor Award 2022 ceremony
Geneva - 21 June 2022 - Congratulations to Madiha Derouazi & Elodie Belnoue for winning the "SMEs" category at the European InventorAward 2022!
Madiha Derouazi and Elodie Belnoue named as joint finalists for European Inventor Award 2022
Geneva, 17 May 2022 – We are very happy and proud to announce that Madiha Derouazi and Elodie Belnoue have been jointly nominated for the EPO's European Inventor Award 2022.
Joint Team Effort Succeeds in Advancing First-in-Cass Triple Combination Immunotherapy to Studies in Patients with Colorectal Cancer
AMAL Therapeutics and ViraTherapeutics, in partnership with their common parent company, Boehringer Ingelheim, are very proud to announce that they have advanced their first-in-class heterologous prime-boost vaccine to Phase 1 studies in patients with colorectal cancer in combination with Ezabenlimab (BI 754091).